Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-11-26
2010-06-01
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S064000, C514S563000
Reexamination Certificate
active
07727964
ABSTRACT:
The present invention relates to inhibitors of post-proline cleaving enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors of the present invention are improved over those in the prior art by selection of particular classes of sidechains in the P1 and/or P2 position of the inhibitor. The compounds of the present invention can have a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease.
REFERENCES:
patent: 4499082 (1985-02-01), Shenvi et al.
patent: 4522752 (1985-06-01), Sisto et al.
patent: 4698327 (1987-10-01), Nagarajan et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 4963655 (1990-10-01), Kinder et al.
patent: 5061811 (1991-10-01), Pinori et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5463124 (1995-10-01), Jacobi et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5574017 (1996-11-01), Gutheil
patent: 5580979 (1996-12-01), Bachovchin
patent: 5585390 (1996-12-01), Duflos et al.
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5679782 (1997-10-01), Rosenberg et al.
patent: 5721214 (1998-02-01), Marlowe et al.
patent: 5776902 (1998-07-01), Bachovchin
patent: 5783556 (1998-07-01), Clark et al.
patent: 5834428 (1998-11-01), Drucker
patent: 5952301 (1999-09-01), Drucker
patent: 5965532 (1999-10-01), Bachovchin
patent: 6011155 (2000-01-01), Villhauer
patent: 6258597 (2001-07-01), Bachovchin et al.
patent: 6300314 (2001-10-01), Wallner et al.
patent: 6355614 (2002-03-01), Wallner
patent: 6703238 (2004-03-01), Bachovchin et al.
patent: 6770628 (2004-08-01), Wallner et al.
patent: 6803357 (2004-10-01), Bachovchin et al.
patent: 6825169 (2004-11-01), Bachovchin et al.
patent: 6890898 (2005-05-01), Bachovchin et al.
patent: 6890904 (2005-05-01), Wallner et al.
patent: 6949514 (2005-09-01), Wallner et al.
patent: 6979697 (2005-12-01), Wallner
patent: 2001/0020006 (2001-09-01), Demuth et al.
patent: 2003/0045228 (2003-03-01), Johnson
patent: 2003/0153509 (2003-08-01), Bachovchin et al.
patent: 2003/0158114 (2003-08-01), Wallner et al.
patent: 2004/0077601 (2004-04-01), Adams et al.
patent: 2004/0152192 (2004-08-01), Bachovchin et al.
patent: 2004/0176307 (2004-09-01), Bachovchin et al.
patent: 2004/0229820 (2004-11-01), Bachovchin et al.
patent: 2005/0037976 (2005-02-01), Wallner et al.
patent: 2005/0049177 (2005-03-01), Bachovchin et al.
patent: 2005/0070482 (2005-03-01), Bachovchin
patent: 2005/0084490 (2005-04-01), Adams et al.
patent: 2005/0203027 (2005-09-01), Bachovchin et al.
patent: 2005/0272703 (2005-12-01), Wallner et al.
patent: 2006/0052310 (2006-03-01), Wallner
patent: 2006/0063719 (2006-03-01), Jesson et al.
patent: WO-89/03223 (1989-04-01), None
patent: WO-93/08259 (1993-04-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO-95/15309 (1995-06-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 95/34538 (1995-12-01), None
patent: WO-96/14857 (1996-05-01), None
patent: WO-96/39385 (1996-12-01), None
patent: WO-97/40832 (1997-11-01), None
patent: WO-98/19998 (1998-05-01), None
patent: WO-98/25644 (1998-06-01), None
patent: WO 98/50046 (1998-11-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO9967279 (1999-12-01), None
patent: WO-00/10549 (2000-03-01), None
patent: WO 00/55126 (2000-09-01), None
patent: WO 00/61789 (2000-10-01), None
patent: WO 00/71135 (2000-11-01), None
patent: WO-01/14318 (2001-03-01), None
patent: WO 01/27138 (2001-04-01), None
patent: WO-01/34594 (2001-05-01), None
patent: WO-01/81337 (2001-11-01), None
patent: WO 03/033524 (2003-04-01), None
patent: WO 03/045228 (2003-06-01), None
patent: WO 03/092605 (2003-11-01), None
E. Swain, ed. Pharm. Med. Pack. News Aug. 1999, 4 pages.
S. Rudikoff, et al. Proc. Natl. Acad. Sci. USA (1982) 79, pp. 1979-1983.
W.S. Messer, “Vasopressin and Oxytocin”, web document updated Apr. 3, 2000; <http://www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm>; 5 pages.
D.E. Smilek, et al. Proc. Natl. Acad. Sci. USA (1991) 88, pp. 9633-9637.
J. Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976) 1-7.
C. Southan. FEBS Letters (2001) 498, pp. 214-218.
A. Lupas, et al. TIBS (1997) 22, p. 399-404.
L.B. Pena, et al. Elect. J. Biotech. (2006) 9(3), pp. 258-262.
C.A. Kettner and A.B. Shenvi. J. Biol. Chem. (1984) 259(24), pp. 15106-15114.
Bell et al., 1983, “Exon duplication and divergence in the human preproglucagon gene”, Nature 304 (5924):368-71.
Conlon, 1988, “Proglucagon-derived peptides: nomenclature, biosynthetic relationships and physiological roles”, Diabetolgia 31(8):536-6.
Coutts et al. Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. I. Variation of the P2 Position of Xaa-boroPro Dipeptides. J. Med. Chem. 39, 2087-2094 (1996).
Deacon et al. Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields an N-Terminally Truncated Peptide that is a Major Endogenous Metabolite in Vivo. J. Clin. Endocrin. 83, 952-957 (1995).
Gutniak et al., 1992, “Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus”, N Engl J Med 326(20):1316-22.
Holst, J. J. & Deacon, C.F. Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes. Diabetes 47, 1663-1670 (1998).
Kawashima et al., 1990, “Pharmacological differentiation of presynaptic M1 muscarinic receptors modulating acetylcholine release from postsynaptic muscarinic receptors in guinea-pig ileum”, Gen Pharmacol 21(1):17-21.
Kinder et al., 1985, “Acylamino boronic acids and difluoroborane analogues of amino acids: potent inhibitors of chymotrypsin and elastase”, J Med Chem 28(12):1917-25.
Kubiak et al., 1994, “Metabolism or mouse growth hormone-releasing factor, mGRF(1-42)OH, and selected analogs from the bovine GRF series in mouse and bovine plasma in vitro”, Pept Res 7(3):153-61.
Lund et al., 1982, “Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem”, Proc Natl Acad Sci U S A 79(2):345-9.
Mentlein et al. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagons-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214, 829-835 (1993).
Mojsov et al., 1986, “Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing”, J Biol Chem 261(25):11880-9.
Mojsov, 1992, “Structural requirements for biological activity of glucagon-like peptide-1”, Int J Pept Protein Res 40(3-4):333-43.
Patzelt et al., 1979, “Identification and processing of proglucagon in pancreatic islets”, Nature 282(5736):260-6.
Pospisilik, John A. et al. Metabolism of Glucagon by Dipeptidyl Peptidase IV (CD26). Regulatory Peptides 96, 133-141.
Schmidt et al., 1985, “Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets”, Diabetologia 28(9):704-7.
Stanely et al., 1989, “Repeated hypothalamic stimulation with neuropeptide Y increases daily carbohydrate and fat intake and body weight gain in female rats”, Physiol Behav 46(2):173-7.
Wilding et al., 1992, “Increased neuropeptide Y content in individual hypothalamic nuclei, but not neuropeptide Y mRNA, in diet-induced obesity in rats”, J Endocrinol 132(2):299-304.
Dupre, 1991, “Influences of the gut on the endocrine pancreas” The Endocrine Pancreas (Raven Press, New York) pp. 253-281.
Weir et al., 1989, “Glucagonlike peptide I (7-37) actions on endocrine pancrease”, Diabetes 38(3):338-42.
Shue et al., 1987, “Amide bond surrogates: a general synthetic route to trans carbon-carbon double bond isosteres”, Tetrahedron Letters 28:3225.
Radhakrishna et al., 1979, “New method for direct conversion o
Foley & Hoag LLP
Gordon Dana M.
Kosar Andrew D
Trustees of Tufts College
LandOfFree
Peptidomimetic inhibitors of post-proline cleaving enzymes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptidomimetic inhibitors of post-proline cleaving enzymes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptidomimetic inhibitors of post-proline cleaving enzymes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4248809